Diagnostics
16 recent notes from companies in this sector. 7 companies tracked.
Thyrocare's Q1 transcript confirms 24% revenue growth, 34% PAT rise
The transcript of Thyrocare's Q1 FY27 earnings call adds no surprises but reaffirms the company's guidance of mid-to-high teens revenue growth for the year.
Aspira Pathlab loses executive director months after appointment
Vaibhav Odhekar resigns for 'personal reasons' effective July 25, 2026, raising management continuity questions at the **₹135 cr** diagnostics firm.
Vimta Labs lands first biologics order, budgets ₹80 cr capex for FY27
Q1 results were already disclosed; the concall adds the domestic biologics win and a ₹80 cr capex plan, including ₹10 cr for the new unit.
Vimta Labs Q1 revenue up 13.7%, EBITDA margin at 36.4%
Steady pharma testing demand and domestic gains offset food testing weakness. Entry into biologics CRD adds a long-term growth lever.
Vimta Labs Q1: Revenue up 12%, PAT up 11% — steady but not a catalyst
In-line quarter with single-digit profit growth; no guidance change. ESOP grant routine.
Dr. Lal PathLabs wins ₹32.66 cr ESOP tax dispute
Tax appellate order overturns a 2024 assessment disallowing the deduction, removing a contingent liability. The amount is small relative to revenue of over ₹2,700 cr.
Vijaya Diagnostic brings back former IPO-year CFO
Narasimha Raju K.A., who led the company through its public listing, returns as CFO effective July 09, 2026. A routine but continuity-affirming appointment for a ₹14,074 cr chain.
Metropolis Q1 revenue up ~16% but growth slows from Q4's 23.6%
Wellness and specialty segments drive volumes; EBITDA margins improve YoY and stay stable sequentially. Full results await board approval.
Krsnaa cuts Rajasthan revenue guidance by half, delays rollout
The flagship PPP project now targets ₹100-150 crore for FY27, down from ₹200-250 crore, as the network launch slips to Q2.
Krsnaa Diagnostics releases Q4 and FY26 management commentary
The company issued a press release alongside its previously disclosed annual results, focusing on retail growth and cash flow.
Krsnaa Diagnostics reports FY26 results with no new surprises
The company confirmed FY26 profit figures previously disclosed to the market. Revenue growth remains modest, and the tax demand remains a known issue.
Krsnaa Diagnostics posts FY26 profit of ₹102.7 cr but the numbers are stale
The audited results disclose no new information beyond what the exchange already has. A ₹62.7 crore tax demand remains unresolved.
Krsnaa's profit is up 24% but it's hiding a ₹63 crore tax demand.
Standalone net profit rose to ₹102.7 crore, but ₹25.9 crore of that was a one-off investment revaluation. Auditors also flagged a ₹62.7 crore tax claim.
Star Imaging reports stagnant FY26 revenue of ₹5,002 lakhs
The diagnostic firm posted a modest profit increase while top-line growth remained effectively flat for the fiscal year.
Suraksha Diagnostic's revenue grows 20%. Profit doesn't follow.
Revenue hit ₹300.68 cr in FY26, up 20.7%. Profit after tax grew just 1.9%. The earnings lag is the story.
Krsnaa Diagnostics gets ₹11.3 cr tax notice, says it will contest
The demand, for 2018-19 and 2019-20, is only 0.6% of market cap. The company is confident of defending on merits.